---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-202446"
form_type: "8-K"
ticker: "CABA"
cik: "0001759138"
company_name: "Cabaletta Bio, Inc."
filed_at: "2026-05-04T23:59:59+00:00"
generated_at: "2026-05-14T23:57:24.089605+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cabaletta Bio prices $150M underwritten offering of 51.7M shares at $2.90; net proceeds ~$141M

## Summary
- 51,725,000 shares offered at $2.90; net proceeds ~$141M after underwriting discounts and expenses.
- Offering includes participation from Bain Capital Life Sciences, Adage Capital, Cormorant Asset Management, and Eli Lilly.
- Preliminary cash & equivalents as of March 31, 2026: $117M.
- Net proceeds to fund expanded clinical development of rese-cel (myositis registrational study and additional indications) and manufacturing for commercial readiness.
- Company expects cash runway into mid-2027 based on current operating plan.

## SEC filing metadata
- accession: 0001193125-26-202446
- form_type: 8-K
- ticker: CABA
- cik: 0001759138
- company_name: Cabaletta Bio, Inc.
- filed_at: 2026-05-04T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/d145767d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-202446
- JSON: https://secwatch.observer/filing/0001193125-26-202446.json
- Plain text: https://secwatch.observer/filing/0001193125-26-202446.txt

## Source-grounded claims
- claim_id: 07a40ec430adb70aa6940d221ca82cc3161fbf0d
  claim: Cabaletta Bio, Inc. reported preliminary financial results for the three months ended March 31, 2026.
  evidence_excerpt: As of March 31, 2026, the Company had approximately $117 million in cash and cash equivalents. This preliminary financial information is subject to completion, and is the responsibility of management and has been prepared in good faith on a consistent basis with prior periods. However, the Company has not reported its financial results for the three months ended March 31, 2026, and its actual results could be materially different from this preliminary financial information.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm
- claim_id: c6693d03255f27267d3b4599c2931ba0a385e1e1
  claim: Cabaletta Bio, Inc. entered into Underwriting Agreement with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. valued at $2.90 per share (effective 2026-05-04).
  evidence_excerpt: On May 4, 2026, Cabaletta Bio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with TD Securities (USA) LLC, Guggenheim Securities, LLC and Cantor Fitzgerald & Co. (collectively, the “Underwriters”), relating to an underwritten registered direct offering (the “Offering”) of 51,725,000 shares (the “Shares”) of the Company’s common stock, $0.00001 par value per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759138/000119312526202446/0001193125-26-202446-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.